Global Blood Therapeutics (NASDAQ:GBT) has been given a $79.00 target price by Oppenheimer in a report released on Tuesday. The firm currently has a “buy” rating on the stock. Oppenheimer’s target price indicates a potential upside of 76.46% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Needham & Company LLC initiated coverage on Global Blood Therapeutics in a research report on Wednesday, September 20th. They set a “buy” rating and a $51.00 price objective for the company. BidaskClub raised Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, November 1st. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a research report on Monday, October 23rd. Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research report on Tuesday, October 10th. Finally, SunTrust Banks raised their price objective on Global Blood Therapeutics to $67.00 and gave the company a “buy” rating in a research report on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $60.71.

Global Blood Therapeutics (NASDAQ GBT) traded down $0.93 on Tuesday, hitting $44.77. The stock had a trading volume of 4,094,500 shares, compared to its average volume of 1,003,992. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the firm posted ($0.58) earnings per share. analysts expect that Global Blood Therapeutics will post -2.55 earnings per share for the current year.

In related news, Director Charles J. Homcy sold 70,000 shares of Global Blood Therapeutics stock in a transaction on Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares of the company’s stock, valued at $2,830,652.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock in a transaction on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the sale, the vice president now directly owns 2,684 shares of the company’s stock, valued at approximately $93,940. The disclosure for this sale can be found here. In the last three months, insiders sold 88,500 shares of company stock valued at $3,003,350. Corporate insiders own 5.30% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. purchased a new position in Global Blood Therapeutics during the second quarter valued at $4,103,000. Emory University purchased a new position in Global Blood Therapeutics during the second quarter valued at $1,442,000. Marcus Capital LLC lifted its position in Global Blood Therapeutics by 25.7% during the second quarter. Marcus Capital LLC now owns 65,350 shares of the company’s stock valued at $1,787,000 after purchasing an additional 13,350 shares in the last quarter. Citigroup Inc. lifted its position in Global Blood Therapeutics by 1,544.9% during the second quarter. Citigroup Inc. now owns 87,819 shares of the company’s stock valued at $2,402,000 after purchasing an additional 82,480 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Global Blood Therapeutics by 211.7% during the second quarter. Goldman Sachs Group Inc. now owns 317,571 shares of the company’s stock valued at $8,686,000 after purchasing an additional 215,690 shares in the last quarter. 90.48% of the stock is owned by institutional investors.

WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/12/oppenheimer-reiterates-79-00-price-target-for-global-blood-therapeutics-gbt.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.